FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ING4-NCAPD2

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ING4-NCAPD2
FusionPDB ID: 39747
FusionGDB2.0 ID: 39747
HgeneTgene
Gene symbol

ING4

NCAPD2

Gene ID

51147

9918

Gene nameinhibitor of growth family member 4non-SMC condensin I complex subunit D2
Synonymsmy036|p29ING4CAP-D2|CNAP1|MCPH21|hCAP-D2
Cytomap

12p13.31

12p13.31

Type of geneprotein-codingprotein-coding
Descriptioninhibitor of growth protein 4brain my036 proteincandidate tumor suppressor p33 ING1 homologcondensin complex subunit 1XCAP-D2 homologchromosome condensation-related SMC-associated protein 1chromosome-associated protein D2
Modification date2020032220200313
UniProtAcc

Q9UNL4

Main function of 5'-partner protein: FUNCTION: Component of HBO1 complexes, which specifically mediate acetylation of histone H3 at 'Lys-14' (H3K14ac), and have reduced activity toward histone H4 (PubMed:16387653). Through chromatin acetylation it may function in DNA replication (PubMed:16387653). May inhibit tumor progression by modulating the transcriptional output of signaling pathways which regulate cell proliferation (PubMed:15251430, PubMed:15528276). Can suppress brain tumor angiogenesis through transcriptional repression of RELA/NFKB3 target genes when complexed with RELA (PubMed:15029197). May also specifically suppress loss of contact inhibition elicited by activated oncogenes such as MYC (PubMed:15029197). Represses hypoxia inducible factor's (HIF) activity by interacting with HIF prolyl hydroxylase 2 (EGLN1) (PubMed:15897452). Can enhance apoptosis induced by serum starvation in mammary epithelial cell line HC11 (By similarity). {ECO:0000250|UniProtKB:Q8C0D7, ECO:0000269|PubMed:15029197, ECO:0000269|PubMed:15251430, ECO:0000269|PubMed:15528276, ECO:0000269|PubMed:15897452, ECO:0000269|PubMed:16387653}.

Q15021

Main function of 5'-partner protein: FUNCTION: Regulatory subunit of the condensin complex, a complex required for conversion of interphase chromatin into mitotic-like condense chromosomes. The condensin complex probably introduces positive supercoils into relaxed DNA in the presence of type I topoisomerases and converts nicked DNA into positive knotted forms in the presence of type II topoisomerases. May target the condensin complex to DNA via its C-terminal domain (PubMed:11136719). May promote the resolution of double-strand DNA catenanes (intertwines) between sister chromatids. Condensin-mediated compaction likely increases tension in catenated sister chromatids, providing directionality for type II topoisomerase-mediated strand exchanges toward chromatid decatenation. Required for decatenation of non-centromeric ultrafine DNA bridges during anaphase. Early in neurogenesis, may play an essential role to ensure accurate mitotic chromosome condensation in neuron stem cells, ultimately affecting neuron pool and cortex size (PubMed:27737959). {ECO:0000269|PubMed:11136719, ECO:0000269|PubMed:27737959}.
Ensembl transtripts involved in fusion geneENST idsENST00000341550, ENST00000396807, 
ENST00000412586, ENST00000423703, 
ENST00000446105, ENST00000486287, 
ENST00000444704, 
ENST00000542492, 
ENST00000315579, ENST00000545962, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score3 X 3 X 3=276 X 6 X 5=180
# samples 36
** MAII scorelog2(3/27*10)=0.15200309344505
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
log2(6/180*10)=-1.58496250072116
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ING4 [Title/Abstract] AND NCAPD2 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ING4 [Title/Abstract] AND NCAPD2 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ING4(6765892)-NCAPD2(6618882), # samples:1
Anticipated loss of major functional domain due to fusion event.ING4-NCAPD2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ING4-NCAPD2 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ING4-NCAPD2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ING4-NCAPD2 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
ING4-NCAPD2 seems lost the major protein functional domain in Hgene partner, which is a epigenetic factor due to the frame-shifted ORF.
ING4-NCAPD2 seems lost the major protein functional domain in Hgene partner, which is a tumor suppressor due to the frame-shifted ORF.
ING4-NCAPD2 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneING4

GO:0006260

DNA replication

16387653

HgeneING4

GO:0006473

protein acetylation

12750254

HgeneING4

GO:0006915

apoptotic process

15251430

HgeneING4

GO:0006978

DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator

16387653

HgeneING4

GO:0007050

cell cycle arrest

15251430

HgeneING4

GO:0008285

negative regulation of cell proliferation

12750254|15251430

HgeneING4

GO:0043065

positive regulation of apoptotic process

16387653

HgeneING4

GO:0043966

histone H3 acetylation

16387653

HgeneING4

GO:0043981

histone H4-K5 acetylation

16387653

HgeneING4

GO:0043982

histone H4-K8 acetylation

16387653

HgeneING4

GO:0043983

histone H4-K12 acetylation

16387653

HgeneING4

GO:0043984

histone H4-K16 acetylation

16387653

HgeneING4

GO:0045892

negative regulation of transcription, DNA-templated

15029197

HgeneING4

GO:0045926

negative regulation of growth

12750254

TgeneNCAPD2

GO:0007076

mitotic chromosome condensation

11136719



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr12:6765892/chr12:6618882)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ING4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across NCAPD2 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000341550ING4chr126765892-ENST00000315579NCAPD2chr126618882+47781563242341400
ENST00000396807ING4chr126765892-ENST00000315579NCAPD2chr126618882+47701482442261400
ENST00000446105ING4chr126765892-ENST00000315579NCAPD2chr126618882+47721502642281400
ENST00000423703ING4chr126765892-ENST00000545962NCAPD2chr126618882+419310911841281336
ENST00000412586ING4chr126765892-ENST00000315579NCAPD2chr126618882+4731109041871395

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000341550ENST00000315579ING4chr126765892-NCAPD2chr126618882+0.0007041620.99929583
ENST00000396807ENST00000315579ING4chr126765892-NCAPD2chr126618882+0.0007199910.99928004
ENST00000446105ENST00000315579ING4chr126765892-NCAPD2chr126618882+0.0007171050.9992829
ENST00000423703ENST00000545962ING4chr126765892-NCAPD2chr126618882+0.001405870.9985941
ENST00000412586ENST00000315579ING4chr126765892-NCAPD2chr126618882+0.0006884740.99931157

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ING4-NCAPD2

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ING4chr126765892NCAPD2chr12661888210936NFQLMRDLDQRTEAFQAAFRAQGPLA
ING4chr126765892NCAPD2chr12661888214841NFQLMRDLDQRTEAFQAAFRAQGPLA
ING4chr126765892NCAPD2chr12661888215041NFQLMRDLDQRTEAFQAAFRAQGPLA
ING4chr126765892NCAPD2chr12661888215641NFQLMRDLDQRTEAFQAAFRAQGPLA

Top

Potential FusionNeoAntigen Information of ING4-NCAPD2 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ING4-NCAPD2_6765892_6618882.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ING4-NCAPD2chr126765892chr126618882156HLA-B18:01TEAFQAAF0.99340.96251119
ING4-NCAPD2chr126765892chr126618882156HLA-B39:06QRTEAFQAA0.99910.9245918
ING4-NCAPD2chr126765892chr126618882156HLA-B39:24QRTEAFQAA0.99840.8411918
ING4-NCAPD2chr126765892chr126618882156HLA-B15:17RTEAFQAAF0.96830.98351019
ING4-NCAPD2chr126765892chr126618882156HLA-B15:16RTEAFQAAF0.96280.98491019
ING4-NCAPD2chr126765892chr126618882156HLA-B35:08DLDQRTEAF0.90820.9163615
ING4-NCAPD2chr126765892chr126618882156HLA-B57:03RTEAFQAAF0.87140.99721019
ING4-NCAPD2chr126765892chr126618882156HLA-A32:13RTEAFQAAF0.7760.97441019
ING4-NCAPD2chr126765892chr126618882156HLA-B15:02DLDQRTEAF0.76530.9695615
ING4-NCAPD2chr126765892chr126618882156HLA-B08:01DLDQRTEAF0.67810.7375615
ING4-NCAPD2chr126765892chr126618882156HLA-A26:08DLDQRTEAF0.17210.6228615
ING4-NCAPD2chr126765892chr126618882156HLA-B27:04QRTEAFQAAF0.99990.7215919
ING4-NCAPD2chr126765892chr126618882156HLA-B27:07QRTEAFQAAF0.99970.753919
ING4-NCAPD2chr126765892chr126618882156HLA-B39:06MRDLDQRTEA0.99540.8681414
ING4-NCAPD2chr126765892chr126618882156HLA-B15:18QRTEAFQAAF0.98890.9122919
ING4-NCAPD2chr126765892chr126618882156HLA-B45:01TEAFQAAFRA0.9880.98371121
ING4-NCAPD2chr126765892chr126618882156HLA-B37:01RDLDQRTEAF0.98750.5755515
ING4-NCAPD2chr126765892chr126618882156HLA-A74:11RTEAFQAAFR0.98240.85981020
ING4-NCAPD2chr126765892chr126618882156HLA-A74:09RTEAFQAAFR0.98240.85981020
ING4-NCAPD2chr126765892chr126618882156HLA-A74:03RTEAFQAAFR0.98240.85981020
ING4-NCAPD2chr126765892chr126618882156HLA-B50:02TEAFQAAFRA0.95660.78871121
ING4-NCAPD2chr126765892chr126618882156HLA-A31:06RTEAFQAAFR0.94530.69141020
ING4-NCAPD2chr126765892chr126618882156HLA-B73:01QRTEAFQA0.9990.9067917
ING4-NCAPD2chr126765892chr126618882156HLA-B44:09TEAFQAAF0.9960.6741119
ING4-NCAPD2chr126765892chr126618882156HLA-C04:07DLDQRTEAF0.99970.9837615
ING4-NCAPD2chr126765892chr126618882156HLA-C05:09DLDQRTEAF0.99970.9904615
ING4-NCAPD2chr126765892chr126618882156HLA-C04:10DLDQRTEAF0.99970.9838615
ING4-NCAPD2chr126765892chr126618882156HLA-C08:15DLDQRTEAF0.99940.9952615
ING4-NCAPD2chr126765892chr126618882156HLA-B73:01QRTEAFQAA0.99750.9403918
ING4-NCAPD2chr126765892chr126618882156HLA-B39:12QRTEAFQAA0.99420.9608918
ING4-NCAPD2chr126765892chr126618882156HLA-B54:01EAFQAAFRA0.99340.83631221
ING4-NCAPD2chr126765892chr126618882156HLA-B78:01EAFQAAFRA0.87280.93391221
ING4-NCAPD2chr126765892chr126618882156HLA-B14:03DLDQRTEAF0.85780.9392615
ING4-NCAPD2chr126765892chr126618882156HLA-B15:31DLDQRTEAF0.83820.9564615
ING4-NCAPD2chr126765892chr126618882156HLA-B15:21DLDQRTEAF0.77670.9594615
ING4-NCAPD2chr126765892chr126618882156HLA-B27:03QRTEAFQAAF0.99880.5929919
ING4-NCAPD2chr126765892chr126618882156HLA-B73:01MRDLDQRTEA0.99150.8699414
ING4-NCAPD2chr126765892chr126618882156HLA-B40:06TEAFQAAFRA0.97650.96421121
ING4-NCAPD2chr126765892chr126618882156HLA-B73:01DQRTEAFQAA0.90350.9446818
ING4-NCAPD2chr126765892chr126618882156HLA-B18:07TEAFQAAF0.99490.94451119
ING4-NCAPD2chr126765892chr126618882156HLA-B18:06TEAFQAAF0.99390.971119
ING4-NCAPD2chr126765892chr126618882156HLA-B18:05TEAFQAAF0.99340.96251119
ING4-NCAPD2chr126765892chr126618882156HLA-B18:04TEAFQAAF0.99170.96791119
ING4-NCAPD2chr126765892chr126618882156HLA-B18:03TEAFQAAF0.99110.95931119
ING4-NCAPD2chr126765892chr126618882156HLA-B18:08TEAFQAAF0.9910.96571119
ING4-NCAPD2chr126765892chr126618882156HLA-B18:11TEAFQAAF0.98430.95691119
ING4-NCAPD2chr126765892chr126618882156HLA-C05:01DLDQRTEAF0.99970.9904615
ING4-NCAPD2chr126765892chr126618882156HLA-C04:01DLDQRTEAF0.99970.9837615
ING4-NCAPD2chr126765892chr126618882156HLA-C04:03DLDQRTEAF0.99970.983615
ING4-NCAPD2chr126765892chr126618882156HLA-C18:01DLDQRTEAF0.99960.9804615
ING4-NCAPD2chr126765892chr126618882156HLA-C08:02DLDQRTEAF0.99940.9952615
ING4-NCAPD2chr126765892chr126618882156HLA-B39:31QRTEAFQAA0.99540.9591918
ING4-NCAPD2chr126765892chr126618882156HLA-A68:02EAFQAAFRA0.99420.84871221
ING4-NCAPD2chr126765892chr126618882156HLA-A69:01EAFQAAFRA0.97710.8321221
ING4-NCAPD2chr126765892chr126618882156HLA-B57:04RTEAFQAAF0.97660.93281019
ING4-NCAPD2chr126765892chr126618882156HLA-A32:01RTEAFQAAF0.93470.99121019
ING4-NCAPD2chr126765892chr126618882156HLA-B57:02RTEAFQAAF0.89480.98141019
ING4-NCAPD2chr126765892chr126618882156HLA-B78:02EAFQAAFRA0.88010.93171221
ING4-NCAPD2chr126765892chr126618882156HLA-B35:20DLDQRTEAF0.81630.96615
ING4-NCAPD2chr126765892chr126618882156HLA-B18:04DLDQRTEAF0.77840.9489615
ING4-NCAPD2chr126765892chr126618882156HLA-B08:18DLDQRTEAF0.67810.7375615
ING4-NCAPD2chr126765892chr126618882156HLA-B18:07DLDQRTEAF0.63330.9238615
ING4-NCAPD2chr126765892chr126618882156HLA-B08:12DLDQRTEAF0.55710.82615
ING4-NCAPD2chr126765892chr126618882156HLA-B27:09QRTEAFQAAF0.99980.5864919
ING4-NCAPD2chr126765892chr126618882156HLA-A74:01RTEAFQAAFR0.98240.85981020

Top

Potential FusionNeoAntigen Information of ING4-NCAPD2 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ING4-NCAPD2_6765892_6618882.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ING4-NCAPD2chr126765892chr126618882156DRB1-0466TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0801TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0802TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0802RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-0802QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-0805TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0808TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0808RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-0808QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-0809TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0809RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-0809QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-0811TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0811RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-0811QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-0813TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0813RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-0813QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-0815TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0815RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-0815QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-0816TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0821TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0821RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-0821QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-0824TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0824RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-0824QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-0826TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0830TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-0830RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-0830QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-0839TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1101TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1101RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1101QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1105TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1105RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1105QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1108TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1108RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1108QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1109TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1109RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1109QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1110TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1110RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1110QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1111TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1112TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1112RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1112QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1115TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1115RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1115QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1119TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1119RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1119QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1124TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1124RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1124QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1127TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1127RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1127QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1128TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1128RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1128QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1129TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1129RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1129QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1130TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1130RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1130QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1131TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1131RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1131QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1132TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1132RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1132QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1133TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1133RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1133QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1137TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1137RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1137QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1139TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1139RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1139QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1145TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1145RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1145QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1149TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1149RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1149QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1151TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1151RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1151QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1153TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1153RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1153QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1154TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1161TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1161RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1161QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1162TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1162RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1162QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1164TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1164RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1164QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1166TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1166RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1166QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1169TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1169RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1169QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1172TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1172RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1173TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1173RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1173QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1174TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1174RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1174QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1175TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1175RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1175QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1179TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1180TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1180RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1180QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1181TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1181RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1181QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1182TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1187TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1187RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1187QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1190TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1190RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1190QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1191TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1191RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1191QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1193TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1193RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1193QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1194TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1194RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1194QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1195TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1195RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1195QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1196TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1196RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1196QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1305TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1305RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1305QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1307TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1307RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1307QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-13100TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-13100RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-13100QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1313TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1314TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1314RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1314QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1321TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1326TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1326RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1326QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1330TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1337TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1337RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1337QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1346TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1346RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1346QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1347TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1347RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1347QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1349TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1349QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1349RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1350TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1350RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1350QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1355TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1355QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1355RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1356TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1356RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1356QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1360TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1360RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1360QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1362TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1362RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1362QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1363TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1382TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1382RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1382QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1385TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1385RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1385QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1386TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1402TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1402RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1403TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1403RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1403QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1409TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1409RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1409QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1413TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1414TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1414RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1414QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1419TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1422TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1422RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1422QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1424TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1425TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1425RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1425QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1427TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1427RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1427QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1430TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1430RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1430QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1436TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1436RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1436QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1440TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1440RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1440QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1441TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1441RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1442TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1442RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1442QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1444TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1444RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1444QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1451TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1451RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1451QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1453TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1453RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1453QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1463TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1463RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1467TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1467RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1467QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1469TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1469RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1469QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1477TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1477RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1477QRTEAFQAAFRAQGP924
ING4-NCAPD2chr126765892chr126618882156DRB1-1485TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1485RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1489TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1494TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1494RTEAFQAAFRAQGPL1025
ING4-NCAPD2chr126765892chr126618882156DRB1-1498TEAFQAAFRAQGPLA1126
ING4-NCAPD2chr126765892chr126618882156DRB1-1498RTEAFQAAFRAQGPL1025

Top

Fusion breakpoint peptide structures of ING4-NCAPD2

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
1203DLDQRTEAFQAAFRING4NCAPD2chr126765892chr126618882156

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ING4-NCAPD2

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN1203DLDQRTEAFQAAFR-7.31338-7.42518
HLA-B14:023BVN1203DLDQRTEAFQAAFR-5.87287-6.91597
HLA-B52:013W391203DLDQRTEAFQAAFR-5.86983-5.98163
HLA-B52:013W391203DLDQRTEAFQAAFR-5.16921-6.21231
HLA-A11:014UQ21203DLDQRTEAFQAAFR-2.35536-3.39846
HLA-A24:025HGA1203DLDQRTEAFQAAFR-9.25732-9.36912
HLA-A24:025HGA1203DLDQRTEAFQAAFR-7.66684-8.70994
HLA-B44:053DX81203DLDQRTEAFQAAFR-5.85306-5.96486
HLA-B44:053DX81203DLDQRTEAFQAAFR-5.02537-6.06847

Top

Vaccine Design for the FusionNeoAntigens of ING4-NCAPD2

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ING4-NCAPD2chr126765892chr1266188821019RTEAFQAAFGAACAGAGGCTTTTCAGGCTGCCTTTC
ING4-NCAPD2chr126765892chr1266188821020RTEAFQAAFRGAACAGAGGCTTTTCAGGCTGCCTTTCGAG
ING4-NCAPD2chr126765892chr1266188821119TEAFQAAFCAGAGGCTTTTCAGGCTGCCTTTC
ING4-NCAPD2chr126765892chr1266188821121TEAFQAAFRACAGAGGCTTTTCAGGCTGCCTTTCGAGCTC
ING4-NCAPD2chr126765892chr1266188821221EAFQAAFRAAGGCTTTTCAGGCTGCCTTTCGAGCTC
ING4-NCAPD2chr126765892chr126618882414MRDLDQRTEATGAGGGACCTAGACCAAAGAACAGAGGCTT
ING4-NCAPD2chr126765892chr126618882515RDLDQRTEAFGGGACCTAGACCAAAGAACAGAGGCTTTTC
ING4-NCAPD2chr126765892chr126618882615DLDQRTEAFACCTAGACCAAAGAACAGAGGCTTTTC
ING4-NCAPD2chr126765892chr126618882818DQRTEAFQAAACCAAAGAACAGAGGCTTTTCAGGCTGCCT
ING4-NCAPD2chr126765892chr126618882917QRTEAFQAAAAGAACAGAGGCTTTTCAGGCTG
ING4-NCAPD2chr126765892chr126618882918QRTEAFQAAAAAGAACAGAGGCTTTTCAGGCTGCCT
ING4-NCAPD2chr126765892chr126618882919QRTEAFQAAFAAAGAACAGAGGCTTTTCAGGCTGCCTTTC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ING4-NCAPD2chr126765892chr1266188821025RTEAFQAAFRAQGPLGAACAGAGGCTTTTCAGGCTGCCTTTCGAGCTCAGGGGCCCCTGG
ING4-NCAPD2chr126765892chr1266188821126TEAFQAAFRAQGPLACAGAGGCTTTTCAGGCTGCCTTTCGAGCTCAGGGGCCCCTGGCTA
ING4-NCAPD2chr126765892chr126618882924QRTEAFQAAFRAQGPAAAGAACAGAGGCTTTTCAGGCTGCCTTTCGAGCTCAGGGGCCCC

Top

Information of the samples that have these potential fusion neoantigens of ING4-NCAPD2

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
Non-CancerING4-NCAPD2chr126765892ENST00000341550chr126618882ENST0000031557943N

Top

Potential target of CAR-T therapy development for ING4-NCAPD2

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ING4-NCAPD2

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ING4-NCAPD2

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource